A company which develops and markets products for the precision medicine & early detection of cancer, Novigenix SA, made an announcement today about the appointment of Francois Martelet as its non-executive director. Mr. Martelet will be an addition to its Board of Directors. Doctor Marletet has more than 25 years of experience at both operational, as well as, corporate level in the biotech & pharmaceutical firms.
The Chief Executive Officer of Novigenix, Doctor Jan Groen passed the following statement regarding the joining of Francois: “Francois is well recognized leader, who has given guidance to various international biotech and pharma companies throughout his career. Particularly, his shared vision and the experience he got lately with the diagnostic companies will be highly valuable to our company as we work towards the development of portfolio of Immuno-Transcriptomics based diagnostics. We welcome him warm heartedly to our company.”
Doctor Martelet stated the following: “Blood Immuno-Trancriptomics sequencing platform which is a unique platform of Novigeniz, gives provision of a novel avenue to the establishment of diagnostics for the detection of cancer at the initial stages, in addition to the fascinating usage in the precision medicine. I am looking forward to work with the entire team at this focal time.”
Recently, Doctor Martelet got retirement as Chief Executive Officer of NetScientific, which is a renowned healthcare investment group in the United Kingdom and focuses on the therapeutics, diagnostics, as well as, healthcare. At the time of his career as a CEO, Francois was also Chairperson of various companies inclusive of ProAxis, and Vortex BioSciences. He earned a doctorate degree from Dijon University. In addition to this, he graduated from Advanced General Management Program in FRance and also got the privilege of attending Senior Executive Programs at Harvard Business School.